Job title: Principal Scientific Researcher & Biomarker Lead
Sarah M. Paul, PhD, is the biomarker lead on several lung oncology trials and projects, including BFAST, an umbrella 1L NSCLC trial enrolls patients based on their liquid biopsy blood test results without the use of tissue. Sarah was a leader in the co-development of the blood tumor mutational burden assay (bTMB) with Foundation Medicine (FMI), which will be part of FMI’s FOneLiquid CDx companion diagnostic assay. Her work was published in Nature Medicine In 2018 and in numerous oral presentations at ASCO and ESMO in 2017-19. After completing her Bachelor’s degree at Brown University, Sarah earned her PhD at Northwestern University in lung developmental biology and did her post-doc at U.C. Berkeley. In 2013, she joined the Oncology Biomarker Development department at Genentech.
Session Q+A 11:00 am
Bringing together the perspectives of the session’s expert speakers, this is your chance to challenge viewpoints, ask any pending questions or bring new discussion points key to advancing clinical trial design, execution and clinical utility demonstration. • How can we maximize patient enrolment in large clinical trials? • Exploring strategies to navigate the analysis of…Read more
day: Day Two
Demonstrating Clinical Utility of Blood Testing 9:00 am
• Genentech’s innovative BFAST trial: Goals, design, and future directions of a blood-only 1L NSCLC trial • Clinical results from BFAST Cohort A: Blood-identified ALK+ patients treated with alectinibRead more
day: Day Two